{"filings":[{"id":1812240,"accession_number":"0001493152-26-034334","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2026-07-23T12:05:26+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bone Biologics raises $3M, extends runway to Q2 2027, advances NB1 study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed $3.0M private placement with healthcare-focused institutional investor; warrants could add up to $6.0M if exercised.","Operating runway extended through Q2 2027; proceeds to fund clinical trials, patent portfolio, and working capital.","NB1 first-in-human pilot study enrollment expected to complete by year-end 2026; interim updates possible.","Validated shelf life of rhNELL-1 protein extended to 29 months, up from 24 months in December 2025.","CEO Jeff Frelick highlights progress on 2026 priorities: clinical execution, product stability, IP protection, capital visibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1694236,"accession_number":"0001493152-26-033586","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2026-07-16T21:25:14+00:00","items":["8.01"],"status":"ready","headline":"Bone Biologics postpones 2026 annual meeting to September 28, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting moved from August 11 to September 28, 2026; new record date August 6, 2026.","Board cites need for additional time for stockholders to consider proxy materials with an added proposal.","Stockholder proposal deadline extended to July 26, 2026, ten days after this 8-K filing.","Meeting location unchanged: 2 Burlington Woods Drive, Ste 100, Burlington, MA at 11:30 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1554276,"accession_number":"0001493152-26-032694","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2026-07-09T20:30:35+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Bone Biologics prices $3.0M private placement with up to $6.0M in warrant proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$3.0M from sale of 2,112,677 pre-funded warrants and Series F/G warrants at $1.419 per unit.","Potential additional ~$6.0M if Series F (5-year) and Series G (18-month) warrants fully exercised at $1.42/share.","Net proceeds ~$2.7M after fees; intended for clinical trials, patent portfolio, and working capital.","H.C. Wainwright acted as exclusive placement agent; received 7.0% cash fee and 126,761 placement agent warrants.","Company to seek stockholder approval for warrant issuance; resale registration statement to be filed within 15 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103845,"accession_number":"0001493152-26-010080","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bone Biologics files prospectus supplement for ATM offering of up to $1.064M in common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filing covers up to $1,064,000 shares of common stock sold at market through H.C. Wainwright as sales agent.","Company previously sold $1.7M under prior shelf; new supplement uses Form S-3 declared effective Sept 2025.","Proceeds from ATM offering will be used for general corporate purposes (not specified further).","Legal opinion of Harter Secrest & Emery LLP on share legality filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103844,"accession_number":"0001493152-26-000896","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bone Biologics highlights 2025 milestones including $5M offering, 24-month shelf life, Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended validated shelf life of rhNELL-1 protein product candidate to 24 months (prior 12/18 months).","Completed $5M registered public offering in Q2 2025 to fund clinical development and IP initiatives.","Regained Nasdaq minimum bid price compliance in June 2025, maintaining public market access.","Filed U.S. patent application for recombinant human NELL-1 bone regeneration technology.","Expects to complete patient enrollment in NB1 first-in-human clinical trial during 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136685,"accession_number":"0001493152-25-012604","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bone Biologics CEO updates on NB1 trial enrollment, shelf life extension, and $5M offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clinical trial enrollment slower than anticipated; expects to complete enrollment by year-end 2025.","Achieved 18-month shelf life for NB1 protein, up from 12 months; plan to extend to 24 months.","Filed U.S. patent application in June 2025 for proprietary rhNELL-1 compositions for bone conditions.","Raised $5M gross in June public offering; expects cash to fund operations into Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153903,"accession_number":"0001641172-25-017165","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bone Biologics closes $5M public offering, net proceeds ~$4.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $5M from 1.25M shares (or pre-funded) plus Series D/E warrants; net ~$4.3M after fees.","Series D warrants (5-year, $4 strike) and Series E warrants (18-month, $4 strike); potential $10M if fully exercised.","Proceeds to fund clinical trials, patent portfolio, and working capital.","H.C. Wainwright acted as exclusive placement agent; fees 7% of gross plus 1% management fee.","After closing, approximately 1.6M shares of common stock outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153902,"accession_number":"0001641172-25-016664","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bone Biologics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Received Nasdaq notice on June 25, 2025 confirming compliance with Listing Rule 5550(a)(2).","Non-compliant since April 7, 2025; regained by maintaining $1.00 closing bid price for 10 consecutive days through June 24, 2025.","Common stock (BBLG) and warrants (BBLGW) continue trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153901,"accession_number":"0001641172-25-013937","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Bone Biologics announces 1-for-6 reverse stock split effective June 10, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split ratio of 1-for-6, effective 12:01 a.m. ET on June 10, 2025.","Common stock to trade on Nasdaq under symbol BBLG starting June 10; warrants unchanged (BBLGW).","New CUSIP for common stock is 098070600; par value remains $0.001 per share.","Fractional shares rounded up to nearest whole share; authorized shares unchanged.","Proportionate adjustments to exercise prices and shares issuable under warrants and equity awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153900,"accession_number":"0001641172-25-013084","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Bone Biologics shareholders approve 30M share increase and 1-for-2.5 to 1-for-10 reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected directors Stroever, Angle, Gagnon, and Meikle; all received >90% of votes cast (excluding broker non-votes).","Approved plan amendment increasing authorized shares by 30M to 30,629,489 for equity awards.","Authorized board to implement reverse stock split in range of 1-for-2.5 to 1-for-10 at its discretion.","Ratified Weinberg & Company as auditor for FY2025; advisory say-on-pay passed with 63% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153899,"accession_number":"0001641172-25-003880","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bone Biologics receives Nasdaq delisting notice for bid price below $1; plans reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on April 7, 2025 for failing minimum bid price of $1 per share for 30 consecutive business days.","Has 180-day compliance period until October 6, 2025 to regain compliance by closing bid price >= $1 for 10 consecutive business days.","Intends to seek stockholder approval for a reverse stock split at upcoming annual meeting to increase share price.","No immediate effect on listing; if not compliant, Nasdaq may delist, subject to appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153898,"accession_number":"0001641172-25-002130","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Bone Biologics sets 2025 annual meeting for May 30; shareholder proposals due April 11","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 Annual Meeting on May 30, 2025; record date and proposals to be detailed in proxy statement.","Deadline for shareholder proposals and director nominations is April 11, 2025 (ten calendar days after this filing).","Submit proposals to Bone Biologics Corporation, Attn: Corporate Secretary, 2 Burlington Woods Dr, Ste 100, Burlington, MA 01803."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189552,"accession_number":"0001493152-24-050025","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bone Biologics updates ATM offering limit to $832,009 after $846k previously sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement resetting ATM with H.C. Wainwright to max $832,009 in common shares.","Previously sold approximately $846,288 under September 27, 2024 prospectus supplement.","Shares offered under Sales Agreement dated September 27, 2024 with H.C. Wainwright & Co.","Legal opinion from Harter Secrest & Emery LLP on share legality filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189551,"accession_number":"0001493152-24-041710","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bone Biologics appoints Phillip Meikle to board, replacing retiring director Don Hankey","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Phillip Meikle appointed to Bone Biologics board effective October 16, 2024.","Meikle founded Biosystems of New England (sold to Stryker in 2019), 30+ years orthopedic/spine experience.","Don R. Hankey retired from board after seven years of service; board size stays at four.","Meikle will be compensated in the same manner as other Bone Biologics directors.","No arrangements or transactions requiring disclosure under Item 404(a) were identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189550,"accession_number":"0001493152-24-039554","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Don Hankey resigns from Bone Biologics board effective Oct 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Don Hankey resigned as director of Bone Biologics effective October 1, 2024.","Resignation was not due to any disagreement with the Company's operations, policies, or practices.","Company expressed appreciation for Mr. Hankey's years of service as a director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206053,"accession_number":"0001493152-24-038583","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bone Biologics enters ATM equity offering agreement with H.C. Wainwright for up to $1.14M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC to sell common stock shares from time to time.","Aggregate market value of shares eligible for sale under the ATM prospectus supplement is $1,143,121.","Commission to Wainwright at 3.0% of gross proceeds; Company to reimburse expenses up to $100,000 plus due diligence fees.","Offering terminates upon sale of $1.14M or termination by either party; Company not obligated to sell any shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206052,"accession_number":"0001493152-24-037146","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bone Biologics stockholders elect directors, approve exec comp, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Don Hankey, Bruce Stroever, Siddhesh Angle, and Robert Gagnon elected directors at Sept. 17, 2024 annual meeting.","Advisory vote on executive compensation passed with 204,831 for, 18,847 against, 1,713 abstaining.","Stockholders ratified Weinberg & Company as independent auditor for FY 2024: 627,025 for, 5,421 against, 4,396 abstaining.","Broker non-votes of 411,451 on director elections and advisory comp vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206051,"accession_number":"0001493152-24-029978","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Bone Biologics raises $2.1M via exercise of warrants, issues new warrants for 1.56M shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Existing warrant holders exercised 781,251 shares at $2.43/share, yielding ~$2.1M gross proceeds.","Company issued new unregistered warrants to purchase 1,562,502 shares at $2.00/share (five-year and 18-month terms).","H.C. Wainwright acted as exclusive placement agent; fees include 7.0% cash fee and placement agent warrants.","Net proceeds to fund clinical trials, patent portfolio, and working capital.","Inducement transaction expected to close August 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223074,"accession_number":"0001493152-24-024426","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"First two patients treated in pilot study of NB1 bone graft device for spine fusion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two patients treated in Australia in multicenter pilot study evaluating NB1 (NELL-1+DBM) for TLIF in degenerative disc disease.","Study targets 30 adult subjects; design reviewed by FDA Division of Orthopedic Devices to support US pivotal trial.","Preclinical studies showed strong safety profile and fusion success; CEO cites $3 billion global spine fusion market opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242568,"accession_number":"0001493152-24-010114","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bone Biologics enters amended CEO agreement with $300K salary, transaction bonus provision","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Jeffrey Frelick receives $300,000 annual base salary, bonus target of 50% of salary, and transaction bonus of 1-2% of deal value upon acquisition.","CFO Deina Walsh granted transaction bonus eligibility of 0.5-1% of deal value via amendment effective March 11, 2024.","Frelick's agreement renews automatically; severance includes one year base salary plus COBRA coverage for one year if terminated without cause.","Both agreements contain standard restrictive covenants and will be filed in the next quarterly report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242567,"accession_number":"0001493152-24-009033","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bone Biologics closes $2.0M public offering of shares and warrants; net proceeds ~$1.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 119,000 shares and 662,251 pre-funded warrants, each with warrants to buy one share at $2.43.","Combined offering price $2.56 per share and warrant; net proceeds ~$1.5M after fees.","Warrants exercisable immediately, expire in 5 years; exercise price $2.43.","Proceeds to fund clinical trials, patent portfolio, and working capital.","After closing, shares outstanding increased to 879,176."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242566,"accession_number":"0001493152-24-008412","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bone Biologics reports NB1 clinical trial progress: 3 sites engaged in Australia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NB1 pilot trial: 30 adults, randomized, evaluating safety & effectiveness in TLIF for DDD.","Three Australian hospital sites engaged after HREC approval; study design reviewed by FDA.","Inclusion: DDD at one level L2-S1, up to Grade 1 spondylolisthesis or retrolisthesis.","Progress supports advancement toward potential US pivotal trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242565,"accession_number":"0001493152-24-002233","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2024-01-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bone Biologics settles breach-of-contract lawsuit for $750,000 cash payment","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Company will pay plaintiffs $750,000 cash within 20 business days of the January 9, 2024 effective date.","Insurance carrier contributes $400,000 less certain retention amounts toward the settlement.","Parties to file joint stipulation to dismiss the action with prejudice; resolution avoids further litigation costs.","Settlement covers claims against both the company and defendant Stephen LaNeve."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242564,"accession_number":"0001493152-24-002010","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bone Biologics appoints Robert Gagnon to board of directors, replacing Erick Lucera","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Gagnon appointed to board effective Jan 8, 2024; Erick Lucera resigned same date.","Gagnon will chair audit committee and serve on compensation and nominating committees.","He brings 20+ years finance experience; currently CFO of Remix Therapeutics.","Board size remains at four members after appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242563,"accession_number":"0001493152-24-001892","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bone Biologics regains Nasdaq minimum bid price compliance; stock continues listing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice confirming compliance with minimum bid price rule (Rule 5550(a)(2)).","Compliance met on Jan 4, 2024 after 10 consecutive trading days with closing bid price over $1.00.","Stock will continue on Nasdaq Capital Market under discretionary panel monitor until June 28, 2024.","Previously notified of deficiency on Sep 27, 2023 for failing to maintain $1.00 closing bid for 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242562,"accession_number":"0001493152-24-000132","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bone Biologics director Erick Lucera resigns pending successor appointment","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erick Lucera resigned as director effective upon appointment of a new director.","Resignation was not due to any disagreement with the company's operations or policies.","No replacement director has been named as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259965,"accession_number":"0001493152-23-045193","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Bone Biologics announces 1-for-8 reverse stock split effective December 20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-8 ratio effective 12:01 a.m. ET on December 20, 2023.","Common stock trades post-split under symbol BBLG; warrants under BBLGW.","New CUSIP for common stock is 098070501; par value remains $0.001.","Authorized shares unchanged; fractional shares rounded up to nearest whole.","Proportionate adjustments to exercise prices and shares issuable under warrants and equity awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259964,"accession_number":"0001493152-23-044661","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Stockholders approve reverse stock split; Nasdaq grants continued listing until Jan 12, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders voted 1,402,685 for, 162,168 against, 16,129 abstain to authorize reverse stock split at ratio 1:5 to 1:20.","Nasdaq Hearings Panel granted continued listing until Jan 12, 2024, subject to milestones including implementing the reverse split and meeting minimum bid price.","Company intends to implement plan to meet milestones before Jan 12 deadline; previously received delisting notice for bid price non-compliance.","Special meeting adjournment proposal was also approved but not needed since first proposal passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259963,"accession_number":"0001493152-23-041982","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Bone Biologics announces registered direct offering of 1.14M shares at $0.64/share, with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$729,200; net proceeds ~$591,000 after fees.","Warrants to purchase up to 1,139,063 shares at $0.52/exercise, 5.5-year term.","H.C. Wainwright acts as placement agent; fees: 7% cash, 1% mgmt, 68,344 warrants.","Closing expected Nov 20, 2023; proceeds for clinical trials, patent portfolio, working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259962,"accession_number":"0001493152-23-038029","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["5.03"],"status":"ready","headline":"Bone Biologics reduces stockholder quorum requirement from majority to one-third","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Bylaw Amendment reducing quorum from majority to at least one-third of outstanding voting power.","Amendment effective immediately as of October 20, 2023.","Change intended to facilitate holding stockholder meetings with lower attendance threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277240,"accession_number":"0001493152-23-034907","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bone Biologics receives Nasdaq delisting notice for bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq staff determination to delist due to failure to maintain $1.00 minimum bid price.","Company plans to request a hearing before Nasdaq Hearings Panel to appeal the delisting determination.","Company is evaluating alternatives to regain compliance; no assurance of success.","If delisted, securities expected to trade on OTC Markets platform.","Company previously under mandatory Panel Monitor, making it ineligible for standard compliance period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277239,"accession_number":"0001493152-23-032347","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bone Biologics stockholders elect directors and approve all proposals at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four director nominees elected: Hankey, Stroever, Lucera, Angle; broker non-votes of 578,270 for each.","Advisory vote on executive compensation approved: 904,764 for, 84,094 against, 307,376 abstentions.","Advisory frequency vote selects every year (958,400 votes); board adopts annual say-on-pay policy.","Ratification of Weinberg & Company as auditor for FY2023: 1,513,051 for, 61,316 against.","First Amendment to 2015 Equity Incentive Plan approved: 863,931 for, 123,150 against, 309,153 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277238,"accession_number":"0001493152-23-023458","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq confirms Bone Biologics compliance with minimum bid price; one-year panel monitor imposed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received letter from Nasdaq Hearings Advisor on June 28, 2023 confirming compliance with Listing Rule 5550(a)(2) for minimum bid price.","Company subject to Panel Monitor through June 27, 2024; any future non-compliance triggers immediate delisting process with no cure period.","During monitoring, failure to meet any continued listing requirement forfeits standard compliance plan and cure periods, risking delisting.","Company's common stock (BBLG) and warrants (BBLGW) trade on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295131,"accession_number":"0001493152-23-021605","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bone Biologics prices $5M underwritten public offering of 2.5M shares at $1.97/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $5.0 million from sale of 2,538,071 shares of common stock at $1.97 per share.","Underwriters granted 45-day over-allotment option to purchase up to 253,807 additional shares.","Offering expected to close on or about June 16, 2023, subject to customary conditions.","EF Hutton, division of Benchmark Investments, acting as sole book-running manager.","Registration statement on Form S-1 (No. 333-271558) declared effective by SEC on June 14, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295130,"accession_number":"0001493152-23-020241","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Bone Biologics effects 1-for-30 reverse stock split effective June 5, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-30 reverse split of common stock and warrants effective June 5, 2023; par value unchanged.","Stockholder approval via written consent on May 1, 2023; no fractional shares, rounding up.","Trading on Nasdaq on split-adjusted basis from June 7, 2023; new CUSIP 098070402 (common) and 098070154 (warrants).","Proportionate adjustments to exercise prices and shares reserved under equity plans and outstanding options/warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295129,"accession_number":"0001493152-23-018373","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bone Biologics receives Nasdaq delisting notice; plans appeal and reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BBLG on May 18, 2023 that its common stock and warrants are subject to delisting for failing to maintain $1.00 bid price.","Company will request a hearing before Nasdaq Hearings Panel to appeal, which stays delisting pending decision.","Stockholders approved a reverse stock split at ratio between 1:20 and 1:50 on May 1, 2023 to help regain bid price compliance.","If delisted, company expects securities to trade on OTC Markets platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334040,"accession_number":"0001493152-22-036161","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2022-12-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Stephen LaNeve resigns from Bone Biologics board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen LaNeve resigned as a director effective December 18, 2022.","Resignation was not due to any disagreement with the company's operations, policies, or practices.","Company expressed appreciation for Mr. LaNeve's years of service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334039,"accession_number":"0001493152-22-033115","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2022-11-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bone Biologics receives Nasdaq delisting notice for bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Nov 17, 2022: common stock closing bid below $1.00 for 30 consecutive business days.","Compliance period of 180 calendar days until May 16, 2023 to regain minimum $1.00 bid price.","May qualify for second 180-day period if meeting other listing standards and notifying Nasdaq of intent to cure.","Company plans to assess potential actions but may be unable to regain compliance and face delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334038,"accession_number":"0001493152-22-029492","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2022-10-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bone Biologics CEO letter details $5.1M financing, plans for 30-patient NB1 trial in Australia by 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $5.1M gross in underwritten public offering of common stock and warrants for clinical trials and working capital.","Modified license agreement with UCLA TDG in May 2022 to defer diligence fees until first product sale.","Engaged MTF Biologics for DBM supply and a CDMO for recombinant protein manufacturing for NB1.","Expects to commence 30-patient pilot study in Australia in 2023 evaluating NB1 in lumbar interbody fusion.","NB1 addresses $3B global market for bone graft substitutes in spine fusion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334037,"accession_number":"0001493152-22-028300","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2022-10-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bone Biologics closes $5.1M public offering of 3.78M units at $1.35/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.1M from offering of 3,777,778 units at $1.35 per unit.","Each unit includes one common share and three Series A, B, C warrants exercisable at $1.62, $1.35, $2.16 respectively.","Warrants expire five years from issuance; Series C warrants eligible for cashless exercise upon $10M volume trigger.","Net proceeds to fund clinical trials, patent portfolio, CRO retention, and working capital.","WallachBeth Capital acted as sole book-runner; over-allotment option partially exercised for 556,037 warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334036,"accession_number":"0001493152-22-028136","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bone Biologics prices $5.1M public offering of 3.78M units at $1.35/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $5.1M from sale of 3,777,778 units; net proceeds estimated ~$4.454M.","Each unit: 1 common share plus Series A ($1.62), B ($1.35), C ($2.16) warrants, 5-year term.","Series C warrant cashless exercise trigger: 15 days after issuance or $10M common stock volume traded.","Underwriters granted 45-day over-allotment option for up to 566,666 additional shares/warrants.","Closing expected October 12, 2022; WallachBeth Capital acting as sole book-running manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351465,"accession_number":"0001493152-22-023895","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2022-08-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bone Biologics shareholders elect directors, approve say-on-pay, and ratify auditor at August 23, 2022 annual meeting.","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected directors Don Hankey, Stephen La Neve, Bruce Stroever, Erick Lucera, Siddhesh Angle with ~7.3M votes each; 666,720 broker non-votes.","Advisory approval of executive compensation passed with 7,271,303 for, 29,002 against, 11,599 abstain.","Ratification of Weinberg & Company as auditor for FY2022 approved with 7,965,696 for, 1,274 against, 11,654 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368827,"accession_number":"0001493152-22-016325","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bone Biologics amends license with UCLA, deferring $8M diligence fee tied to future sales milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Third Amendment extends development milestones; UCLA defers $8M diligence fee until first sale of licensed product.","$8M fee payable in tranches: $2M at $50M net sales, $2M at $100M, $4M at $200M cumulative net sales.","Obligation survives termination; assets cannot be transferred without assigning fee or paying within 10 days.","New milestones include initiating Phase I/II pilot study by Dec 31, 2024, and pegylated product milestones through 2030s.","Company must spend at least $1M per year on pre-clinical/clinical development until Phase III completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368826,"accession_number":"0001493152-22-014716","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2022-05-23T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Bone Biologics sets 2022 Annual Meeting for August 23; stockholder proposal deadline June 23","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2022 Annual Meeting scheduled for August 23, 2022; record date June 24, 2022.","No 2021 Annual Meeting held; revised deadlines apply for stockholder proposals.","Deadline for Rule 14a-8 proposals and director nominations is June 23, 2022.","Proposals must be sent to Corporate Secretary at Burlington, MA address."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388065,"accession_number":"0001493152-22-006230","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2022-03-08T23:59:59+00:00","items":["1.01","5.03","3.1","8.01","9.01"],"status":"ready","headline":"Bone Biologics secures exclusive DBM supply from MTF for rhNELL-1 spine fusion product","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive supply agreement with MTF Biologics for demineralized bone matrix (DBM) as carrier for rhNELL-1 bone graft substitute.","DBM will supply planned 30-patient pilot study and subsequent U.S. pivotal study in spine fusion.","Five-year term with extension option; targeting the $3 billion spine fusion market.","Also amended bylaws: stockholders with 15% voting power can call special meetings; exclusive Delaware forum for certain actions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406004,"accession_number":"0001493152-21-032259","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2021-12-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bone Biologics enters revised employment agreement with CFO, base salary $200K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Employment agreement effective Jan 3, 2022; at-will; base salary $200,000.","Annual target bonus of 25% of base salary, subject to board-set objectives.","Stock option grant of 25,000 shares with 2-year maturity at market price.","CFO Deina H. Walsh has served since Nov 2014; new agreement updates terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406003,"accession_number":"0001493152-21-025784","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2021-10-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bone Biologics closes $7.9M public offering, uplists to Nasdaq Capital Market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed public offering of 1,510,455 units at $5.25/unit for gross proceeds of $7.9M.","Each unit consists of one share of common stock and one warrant (exercise $6.30, 5-year term).","Warrants are immediately exercisable; underwriter has 45-day option for up to 226,568 additional shares/warrants.","Company effectuated a 1-for-2.5 reverse stock split effective Oct 12, 2021.","Shares and warrants began trading on Nasdaq Capital Market on Oct 13, 2021 under BBLG and BBLGW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406002,"accession_number":"0001493152-21-025492","cik":1419554,"company_name":"Bone Biologics Corp","ticker":"BBLG","form_type":"8-K","filed_at":"2021-10-15T23:59:59+00:00","items":["1.01","5.03","8.01","9.01"],"status":"ready","headline":"Bone Biologics prices $7.9M public offering, uplists to Nasdaq, effects 1-for-2.5 reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,510,455 units at $5.25/unit raised $7.9M gross; units consist of 1 share + 1 warrant (strike $6.30, 5-year term).","Common stock and warrants began trading on Nasdaq Capital Market Oct 13 under symbols BBLG and BBLGW.","Company effected 1-for-2.5 reverse stock split effective Oct 12, 2021.","Underwriters granted 45-day over-allotment option for up to 226,568 additional shares and/or warrants.","WallachBeth Capital acted as sole book-running manager; closing expected Oct 15, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2226122.7936507934,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}